Reagan-Udall Foundation and Friends of Cancer Research form COVID-19 Evidence Accelerator focused on RWE

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Reagan-Udall Foundation for the FDA and Friends of Cancer Research, created the Evidence Accelerator, a public-private partnership combining the efforts of academic, government, and private sector organizations applying data analytics to accelerate the understanding of COVID-19.

Mobilizing major data organizations, government and academic researchers, and health systems, the Evidence Accelerator builds on the work of its partners to maximize the use of real-world data. Contributing researchers will engage in weekly meetings to present and critically discuss findings from different data sources. In addition, the Evidence Accelerator will facilitate parallel analyses of questions to identify patient characteristics, treatment patterns, and management strategies for COVID-19.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login